HK1179248A1 - Novel spiroheterocyclic compounds as mglu5 antagonists - Google Patents

Novel spiroheterocyclic compounds as mglu5 antagonists

Info

Publication number
HK1179248A1
HK1179248A1 HK13106089.4A HK13106089A HK1179248A1 HK 1179248 A1 HK1179248 A1 HK 1179248A1 HK 13106089 A HK13106089 A HK 13106089A HK 1179248 A1 HK1179248 A1 HK 1179248A1
Authority
HK
Hong Kong
Prior art keywords
mglu5 antagonists
spiroheterocyclic compounds
novel
novel spiroheterocyclic
compounds
Prior art date
Application number
HK13106089.4A
Other languages
English (en)
Chinese (zh)
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Riva
Luciano Guarneri
Davide Graziani
Toma Carlo De
Katia Dimitrova Karamfilova
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of HK1179248A1 publication Critical patent/HK1179248A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK13106089.4A 2010-07-09 2013-05-23 Novel spiroheterocyclic compounds as mglu5 antagonists HK1179248A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36294410P 2010-07-09 2010-07-09
PCT/EP2011/061690 WO2012004400A1 (en) 2010-07-09 2011-07-08 Novel spiroheterocyclic compounds as mglu5 antagonists

Publications (1)

Publication Number Publication Date
HK1179248A1 true HK1179248A1 (en) 2013-09-27

Family

ID=44503767

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13106089.4A HK1179248A1 (en) 2010-07-09 2013-05-23 Novel spiroheterocyclic compounds as mglu5 antagonists

Country Status (17)

Country Link
US (1) US8580962B2 (xx)
EP (1) EP2590985B1 (xx)
JP (1) JP2013529673A (xx)
KR (1) KR101862626B1 (xx)
CN (1) CN103097391B (xx)
AU (1) AU2011275696B2 (xx)
BR (1) BR112013000529B1 (xx)
CA (1) CA2800930C (xx)
EA (1) EA023020B1 (xx)
ES (1) ES2492694T3 (xx)
HK (1) HK1179248A1 (xx)
IL (1) IL223330A (xx)
MX (1) MX2013000300A (xx)
NZ (1) NZ603868A (xx)
SG (1) SG186107A1 (xx)
UA (1) UA110343C2 (xx)
WO (1) WO2012004400A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
AU2015373392B2 (en) * 2014-12-29 2020-05-14 Recordati Ireland Limited Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors
MA42508B1 (fr) 2015-06-03 2020-05-29 Hoffmann La Roche Dérivés d'éthynyle
CN107903265A (zh) * 2017-11-21 2018-04-13 毛琳琳 一种新型螺环类杀虫剂的制备方法及应用
CN116351472B (zh) * 2023-02-22 2024-06-25 万华化学集团股份有限公司 一种催化精馏生产异氰酸酯的制备方法和系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
US6369222B1 (en) * 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP2061775A2 (en) * 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
AU2011275696A1 (en) 2012-12-20
US20120059015A1 (en) 2012-03-08
EA201270799A1 (ru) 2013-05-30
WO2012004400A1 (en) 2012-01-12
NZ603868A (en) 2014-08-29
KR101862626B1 (ko) 2018-05-31
MX2013000300A (es) 2013-02-27
SG186107A1 (en) 2013-01-30
ES2492694T3 (es) 2014-09-10
JP2013529673A (ja) 2013-07-22
KR20130097153A (ko) 2013-09-02
BR112013000529A2 (pt) 2016-05-24
EP2590985B1 (en) 2014-05-14
US8580962B2 (en) 2013-11-12
AU2011275696B2 (en) 2016-02-11
EA023020B1 (ru) 2016-04-29
IL223330A0 (en) 2013-02-03
IL223330A (en) 2015-09-24
BR112013000529B1 (pt) 2019-11-19
CN103097391B (zh) 2015-04-08
EP2590985A1 (en) 2013-05-15
CA2800930C (en) 2018-08-21
CA2800930A1 (en) 2012-01-12
UA110343C2 (xx) 2015-12-25
CN103097391A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2627178A4 (en) QUINAZOLINONE-LIKE COMPOUNDS AS CRTH2 ANTAGONISTS
GB201005589D0 (en) Novel compounds
GB201012686D0 (en) Novel compounds
HK1179248A1 (en) Novel spiroheterocyclic compounds as mglu5 antagonists
GB201007791D0 (en) Novel compounds
GB201005811D0 (en) Novel compounds A3
GB201020909D0 (en) Novel compounds
GB201020622D0 (en) Novel compounds
GB201020607D0 (en) Novel compounds
GB201019547D0 (en) Novel compounds
GB201019576D0 (en) Novel compounds
GB201019480D0 (en) Novel compounds
GB201019575D0 (en) Novel compounds
GB201014231D0 (en) Novel compounds
GB201014232D0 (en) Novel compounds
GB201012924D0 (en) Novel compounds
GB201012922D0 (en) Novel compounds
GB201010514D0 (en) Novel compounds
GB201010513D0 (en) Novel compounds
GB201010512D0 (en) Novel compounds
GB201010506D0 (en) Novel compounds
GB201010509D0 (en) Novel compounds
GB201010511D0 (en) Novel compounds
GB201010516D0 (en) Novel compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210710